Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.
Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.
复制标题
非编码RNA作为克罗恩病肠纤维化的有希望的诊断生物标志物和治疗靶点：从长凳到床边的路径。
DOI：
10.1093/ibd/izaa321
复制
发表时间：
2020-12
影响因子：
4.9
通讯作者：
Longyuan Zhou;Si-nan Lin;F. Rieder;Min-Hu Chen;Shenghong Zhang;R. Mao
中科院分区：
文献类型：
--
作者：
Longyuan Zhou;Si-nan Lin;F. Rieder;Min-Hu Chen;Shenghong Zhang;R. Mao
纤维化是器官损伤和衰竭的主要途径，占全球死亡人数的三分之一以上。肠纤维化引起不可逆的和严重的临床并发症，如狭窄和梗阻，继发于复杂的发病机制。在促纤维化可溶性因子的刺激下，间充质细胞的过度活化通过典型的转化生长因子-β/Smads信号通路或其他途径（如上皮-间充质转化和内皮-间充质转化）导致肠纤维化中细胞外基质沉积。在最近的研究中，非编码RNA（ncRNA）在纤维化疾病中的重要性突出，因为ncRNA在调节上述纤维化反应中表现出显著的多种生物学功能。本文综述了ncRNA在肠纤维化中的作用，包括新出现的长ncRNA和环状RNA。值得注意的是，基于其他器官纤维化疾病的临床试验，讨论了ncRNA作为诊断生物标志物和治疗靶点在肠纤维化管理中的翻译潜力。这次审查的要点包括：·ncRNA的特性与肠纤维化发生机制·ncRNA的广泛参与（尤其是新兴的长ncRNA和环状RNA）在肠纤维化中的作用，包括转化生长因子-β信号传导、上皮-间充质转化/内皮-间充质转化，·基于来自其他器官中纤维化疾病的临床试验，ncRNA在肠纤维化的诊断和治疗中的翻译潜力。
Fibrosis is a major pathway to organ injury and failure, accounting for more than one-third of deaths worldwide. Intestinal fibrosis causes irreversible and serious clinical complications, such as strictures and obstruction, secondary to a complex pathogenesis. Under the stimulation of profibrotic soluble factors, excessive activation of mesenchymal cells causes extracellular matrix deposition via canonical transforming growth factor-β/Smads signaling or other pathways (eg, epithelial-to-mesenchymal transition and endothelial-to-mesenchymal transition) in intestinal fibrogenesis. In recent studies, the importance of noncoding RNAs (ncRNAs) stands out in fibrotic diseases in that ncRNAs exhibit a remarkable variety of biological functions in modulating the aforementioned fibrogenic responses. In this review, we summarize the role of ncRNAs, including the emerging long ncRNAs and circular RNAs, in intestinal fibrogenesis. Notably, the translational potential of ncRNAs as diagnostic biomarkers and therapeutic targets in the management of intestinal fibrosis is discussed based on clinical trials from fibrotic diseases in other organs. The main points of this review include the following: • Characteristics of ncRNAs and mechanisms of intestinal fibrogenesis • Wide participation of ncRNAs (especially the emerging long ncRNAs and circular RNAs) in intestinal fibrosis, including transforming growth factor-β signaling, epithelial-to-mesenchymal transition/endothelial-to-mesenchymal transition, and extracellular matrix remodeling • Translational potential of ncRNAs in the diagnosis and treatment of intestinal fibrosis based on clinical trials from fibrotic diseases in other organs.